Document Detail


Chymopapain chemonucleolysis in lumbar disk disease.
MedLine Citation:
PMID:  123015     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Experience with chymopapain chemonucleolysis in 1,200 cases of lumbar disk disease indicates that it is an effective method of relieving pain resulting from an abnormal intervertebral disk. Complications were few; anaphylaxis occurring immediately after injection was by far the most serious. With the use of a corticosteroid and an antihistamine in preoperative preparation, the incidence of anaphylaxis had dropped, although it still occurs. On long-term follow-up, chemonucleolysis appears to be as good as laminectomy in properly selected cases.
Authors:
L L Wiltse; E R Widell; H A Yuan
Related Documents :
16192845 - Paroxetine-associated spontaneous sexual stimulation.
23824465 - Are the precapillary sphincters and metarterioles universal components of the microcirc...
19169095 - Finasteride-induced myalgia and hyperckemia.
9988365 - Successful challenge with clozapine in a history of eosinophilia.
2720875 - Difficult tracheal extubation.
4004005 - Confusion of a poststreptococcal syndrome complicated by uveitis with mucocutaneous lym...
Publication Detail:
Type:  Comparative Study; Journal Article    
Journal Detail:
Title:  JAMA     Volume:  231     ISSN:  0098-7484     ISO Abbreviation:  JAMA     Publication Date:  1975 Feb 
Date Detail:
Created Date:  1975-05-13     Completed Date:  1975-05-13     Revised Date:  2014-09-17    
Medline Journal Info:
Nlm Unique ID:  7501160     Medline TA:  JAMA     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  474-9     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anaphylaxis / chemically induced
Animals
Back Pain / drug therapy
Dogs
Drug Evaluation
Drug Evaluation, Preclinical
Follow-Up Studies
Humans
Injections, Spinal
Intervertebral Disc / drug effects*,  radiography
Intervertebral Disc Displacement / drug therapy*,  radiography
Myelography
Peptide Hydrolases / administration & dosage,  adverse effects,  therapeutic use*
Rabbits
Sciatica / drug therapy
Time Factors
Chemical
Reg. No./Substance:
EC 3.4.-/Peptide Hydrolases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevalence of Dictyocaulus viviparus infection in Rocky Mountain elk in Teton County, Wyoming.
Next Document:  Blood flow velocity in the carotid artery as a measure of myocardial contractility.